Literature DB >> 6802679

Reversal of persistent anovulation in polycystic ovarian disease by administration of chronic low-dose follicle-stimulating hormone.

M M Kamrava, M M Seibel, M J Berger, I Thompson, M L Taymor.   

Abstract

Low doses of follicle-stimulating hormone (FSH) were administered once daily to two consecutive patients with polycystic ovarian disease (PCOD) for therapy of infertility. Serial blood samples were obtained for gonadotropins and ovarian steroid determinations during the period of FSH administration. Exogenous FSH resulted in an initial and concomitant decrease in serum androstenedione (A), estrone (E1), and luteinizing hormone (LH), with an increase in estradiol (E2) and FSH. Subsequent changes in the above-mentioned hormonal levels were typical of a normal ovulatory cycle, with the exception of FSH, which continued to rise in the second half of the follicular phase. This was attributed to the exogenous administration of FSH. Both patients became pregnant in their first induced ovulatory cycle by administration of chronic low-dose FSH. These preliminary data demonstrate (1) a correction of the biochemical imbalance characteristic of PCOD, (2) successful ovulation induction, and (3) restoration of fertility in PCOD treated with chronic low-dose FSH.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6802679     DOI: 10.1016/s0015-0282(16)46159-5

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  3 in total

1.  Low multiple pregnancy rates and reduced frequency of cancellation after ovulation induction with gonadotropins, if eventual supernumerary follicles are aspirated to prevent polyovulation.

Authors:  C De Geyter; M De Geyter; E Nieschlag
Journal:  J Assist Reprod Genet       Date:  1998-03       Impact factor: 3.412

Review 2.  Progress in ovulation induction with gonadotropins.

Authors:  P R Gindoff; R Jewelewicz
Journal:  Bull N Y Acad Med       Date:  1989-06

Review 3.  Infertility in polycystic ovary syndrome: focus on low-dose gonadotropin treatment.

Authors:  Anwen Gorry; Davinia M White; Stephen Franks
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.